


OXFORD

Patents for Chemicals, Pharmaceuticals, and Biotechnology

Fundamentals of Global Law,
Practice, and Strategy

SIXTH EDITION

Philip W. Grubb
Peter R. Thomsen
Gordon Wright
& Thomas Hoxie



PATENTS
FOR CHEMICALS,
PHARMACEUTICALS,
AND
BIOTECHNOLOGY

Fundamentals of Global Law, Practice,
and Strategy

SIXTH EDITION

by
PHILIP W. GRUBB
PETER R. THOMSEN
GORDON WRIGHT
AND
THOMAS HOXIE

OXFORD
UNIVERSITY PRESS

OXFORD
UNIVERSITY PRESS

Great Clarendon Street, Oxford, OX2 6DP,
United Kingdom

Oxford University Press is a department of the University of Oxford.
It furthers the University's objective of excellence in research, scholarship,
and education by publishing worldwide. Oxford is a registered trade mark of
Oxford University Press in the UK and in certain other countries

© Philip W. Grubb, Peter R. Thomsen, Gordon Wright & Thomas Hoxie 2016

The moral rights of the authors have been asserted

Fifth Edition published in 2010

Sixth Edition published in 2016

Impression: 1

All rights reserved. No part of this publication may be reproduced, stored in
a retrieval system, or transmitted, in any form or by any means, without the
prior permission in writing of Oxford University Press, or as expressly permitted
by law, by licence or under terms agreed with the appropriate reprographics
rights organization. Enquiries concerning reproduction outside the scope of the
above should be sent to the Rights Department, Oxford University Press, at the
address above

You must not circulate this work in any other form
and you must impose this same condition on any acquirer

Crown copyright material is reproduced under Class Licence
Number C01P0000148 with the permission of OPSI
and the Queen's Printer for Scotland

Published in the United States of America by Oxford University Press
198 Madison Avenue, New York, NY 10016, United States of America

British Library Cataloguing in Publication Data
Data available

Library of Congress Control Number: 2016950217

ISBN 978-0-19-968473-1

Printed and bound by
CPI Group (UK) Ltd, Croydon, CR0 4YY

Links to third party websites are provided by Oxford in good faith and
for information only. Oxford disclaims any responsibility for the materials
contained in any third party website referenced in this work.

PREFACE TO THE SIXTH EDITION

As it is now over ten years since I was last actively employed in the patent profession, I felt that I needed the assistance of co-authors who are still active, or at least very recently retired, to keep the book up to date on recent developments. Peter Thomsen, who was co-author of the previous edition, and who is a European Patent Attorney and an expert on the interplay between regulatory and patent law, is mainly responsible for Chapter 24. My former Novartis colleague Thomas Hoxie, qualified both as a US and a European Patent Attorney, has contributed an update of all aspects of US law and practice, especially Chapter 25. Finally, Gordon Wright, who has long experience as a European Patent Attorney in the pharmaceutical industry, and who recently retired from private practice, has contributed to passages on UK and European law.

There have indeed been many new developments since the last edition appeared. Some are positive, such as the fundamental change in US patent law from a first-to-invent system to one of 'first-inventor-to-file', implying the gradual disappearance of interference proceedings. Others are less so, including some recent case law both in the US and in the European Patent Office. One at least is catastrophic. The result of the UK referendum of 23 June 2016 means that the UK will almost certainly leave the EU by the end of 2019 at the latest. There was no time to deal with this situation at length in the book, but a short preface at page xxv outlines the likely effects on UK patent law. Other aspects of IP, particularly trademarks and copyright, but also matters such as competition law, orphan drug protection, and parallel imports, will be even more affected.

This book started life as a slim volume entitled 'Patents for Chemists' back in 1982, at the instigation of Prof. Graham Richards, and has gone through a further five editions since then. This edition will be the last in which I shall be involved. I hope that over the years this book has been helpful, and sometimes entertaining, to its target readership of new entrants to the patent profession as well as to others. Again, I thank my wife Kay for her patience and support over all this time.

TABLE OF CASES

UNITED KINGDOM

A & H's Application (1927) 44 RPC 298 (SG)	15.53
AB Draco's SPC Application [1996] RPC 417 (Pat Ct)	13.63
Actavis Group PTC EHF & Anor v Pharmacia LLC [2014] EWHC 2611 (Pat)	11.77
Actavis UK Ltd v Merck Ltd [2008] EWCA (Civ) 444	10.08, 13.54
Albright & Wilson's Patent [1994] SRIS O/142/94	11.16
Auchincloss v Agricultural & Veterinary Supplies Ltd [1997] RPC 649	22.09
BASF v Soc. Chim. du Rhone [1898] 15 RPC 359 (CA)	17.50
Beecham v Bristol Laboratories [1977] FSR 215 (HL)	13.07
Beecham Group Ltd's Application [1980] RPC 261 (CA)	12.27
Beloit v Valmet [1996] FSR 718 (CA)	7.33
Biogen v Medeva [1995] RPC 68 (CA)	11.52
Biogen v Medeva [1997] RPC 1 (HL)	11.52, 12.28, 14.27, 14.57, 14.60–14.61, 14.63, 18.41
Blacklight's Application [2008] EWHC 2763 (Pat)	4.36
Bristol-Myers Squibb v Baker Norton Pharmaceuticals & NaPro Biotherapeutics [2001] RPC 1 (CA)	13.54
BUSM v Simon Collier (1910) 27 RPC 567 (HL)	10.06
Cairnstores Ltd v AB Hassle [2002] FSR 35 (Pat Ct)	11.07
Catnic Components Ltd v Hill & Smith Ltd [1982] RPC 183 (HL)	22.08–22.09, 22.17, 22.19, 22.28
Chiron v Organon [1996] RPC 535 (Pat Ct, CA)	24.04
Cipla Limited v Glaxo Group Limited [2004] EWHC 477 (Pat)	13.28
Clark v Adie [1877] 2 App Cas 315	22.07
Coflexip SA v Stolt Offshore MS Ltd [2004] FSR 7 (Pat Ct)	11.08
Coin Controls v Suzo [1997] FSR 660	22.54
Conor v Angiotech [2008] UKHL 49	4.28
Darcy v Allein [1602] 1 WPC 1 (Court of Queen's Bench)	1.11
Dr Reddy's Laboratories v Eli Lilly [2008] UKHC 2345 (Pat)	12.13
Dr Reddy's Laboratories v Eli Lilly [2009] EWCA Civ 1362	12.17–12.19, 12.22
Du Pont v UK Intellectual Property Office [2009] EWCA Civ 966	2.15
Du Pont's (Witsiepe's) Patent [1982] FSR 303 (HL)	12.17
Dunlop v Moseley (1904) 21 RPC 274 (CA)	10.06
Dyson v Hoover [2002] RPC 465 (CA)	10.63
Edison Bell v Smith (1894) 11 RPC 457 (CA)	4.22
Egyr's Patent [1981] RPC 99 (Pat Ct)	12.40
EI Du Pont Nemours & Co, In the Matter of, [2009] EWHC 1112 (Ch)	9.46
Electrolux v Hudson [1977] FSR 312 (Ch D)	20.27
Eli Lilly & Co v Human Genome Sciences Inc [2008] EWHC 1903 (Pat)	4.31
EMI v Lissen [1938] 56 RPC 23 (HL)	2.06
Genentech v Wellcome [1989] RPC 147 (CA)	14.44
General Tire v Firestone [1972] RPC 457 (CA)	4.17, 23.07
Generics (UK) v Daiichi Pharmaceutical Co Ltd and anor [2009] EWCA Civ 646	12.29

Table of Cases

Gerber Garment Technology Inc v Lectra Systems Ltd [1995] RPC 383 (CA)	10.64
Gillette Safety Razor Co v Anglo-American Trading Co (1913) 30 RPC 465 (HL)	22.69
Greater Glasgow Health Board's Application [1996] RPC 207 (Pat Ct)	20.32
Harris' Application [1985] RPC 19 (Pat Ct)	20.32
Hospira UK Ltd v Genentech Inc [2014] EWHC 3857 (Pat)	12.45, 18.26
Idenix Pharmaceuticals v Gilead and others [2014] EWHC 3916 (Pat)	13.08
I.G. Farbenindustrie's Patents (1930) 47 RPC 289	12.16
Improver Corp v Remington Consumer Products Ltd [1989] RPC 69 (CA)	22.14–22.15, 22.17–22.18
Improver Corp v Remington Consumer Products Ltd [1990] FSR 181 (Pat Ct)	22.14–22.15, 22.17–22.18
Incandescent Gas Light Co v Cantelo (1895) 12 RPC 262 (QB)	10.22
Intel v Via [2003] FSR 574 (CA)	24.50
IPcom GmbH & Co Kg v HTC Europe Co Ltd & Ors [2013] EWCA Civ 1496	11.77
Ivax Pharmaceuticals v AstraZeneca [2004] EWHC 1264	11.77
Kakkar v Szelke [1989] FSR 225 (CA)	20.68
Kelly and Chiu v GE Healthcare [2009] EWHC 181 (Pat)	20.43
Kirin-Amgen Inc v Hoechst Marion Roussel [2004] UKHL 46	18.01, 22.00
Kirin-Amgen Inc v Roche Diagnostics/Kirin-Amgen Inc v Transkaryotic Inc Therapies [2002] RPC 1 (Pat Ct)	1.63, 14.63
Kirin-Amgen Inc v Transkaryotic Therapies Inc [2004] RPC 31 (CA)	14.64
Kirin-Amgen Inc v Transkaryotic Therapies Inc [2005] RPC 9 (HL)	10.51, 22.18–22.19
Laboratorios Almirall SA v Boehringer Ingelheim International GmbH [2009] EWHC 102 (Pat)	17.33
Lenzing's Application [1997] RPC 245 (Pat Ct)	7.38
Les Laboratoires Servier, Servier Laboratories Ltd v Apotex Inc & Ors [2007] EWHC 1538 (Pat)	12.41
Liardet v Johnson (1778) 1 WPC 53	1.16
Lilly Icos LLC v Pfizer Ltd [2002] FSR 809 (CA)	18.46
Lundbeck v Generics (UK) and ors [2008] EWCA Civ 311	12.28, 14.60
Macdonald v Graham [1994] RPC 407 (CA)	10.17
Markem Corp v Zipher Ltd [2005] RPC 31 (CA)	20.63
Matshusita Electric Industrial Co Ltd and ors v UK Intellectual Property Office [2008] RPC 35 (Pat Ct)	9.12
Merck v Generics (UK) [2003] EWHC 2842 (Pat)	22.07
Merrell Dow v Norton [1996] RPC 76 (HL)	13.11
Microbeads v Vinhurst Road Markings [1976] RPC 19 (CA)	10.24
Mobil Oil Corp's Application (1970) FSR 265 (PAT)	17.46
Monsanto Technology LLC v Cargill International SA [2007] EWHC 2257 (Pat)	15.26, 22.34
Monsanto v Stauffer [1985] FSR 55 (Pat Ct)	10.46, 22.65
Napp Pharmaceutical Holdings Ltd v Ratiopharm GmbH and Sandoz Ltd [2009] EWCA Civ 252	12.35
National Phonograph Co of Australia Ltd v Menck (1911) 28 RPC 229 (PC)	10.22
Nobel v Anderson (1894) 11 RPC 115 (Ch D)	22.07
Novartis and others v Focus Pharmaceuticals and others [2015] EWHC 1068 (Pat)	13.31
Novartis v Hospira [2013] EWHC 516 (Pat); [2013] EWCA Civ 1663	13.48
Olin Matheson v Biorex [1970] RPC 157 (Ch D)	12.06
Parks-Cramer v Thornton [1966] RPC 407 (CA)	4.22
Patchett v Sterling Engineering Co (1955) 72 RPC 50 (HL)	20.28
Pharmacia Corp v Merck & Co Inc [2002] ENPR 10 (CA); [2002] RPC 777 (CA)	18.45, 22.18
Pioneer Electronics Capital Inc v Warner Music Manufacturing Europe GmbH [1997] RPC 757 (CA)	10.17, 22.32

Table of Cases

Pozzoli SPA v BDMO SA [2007] EWCA Civ 588	4.23, 4.42, 7.40, 10.55
Pressers and Moody v Haydon (1909) RPC 58 (Ch D)	15.50
R v Comptroller-General of Patents <i>ex p</i> Penife's International Ltd [2004] RPC 37	6.14
Ranbaxy UK Ltd v Warner-Lambert Company [2005] EWHC 2142 (Patents) and [2006]	12.20
Raychem's Application [1986] RPC 547 (Pat Ct)	11.22
Rockwater v Technip France SA (formerly Coflexip SA) [2004] EWCA Civ 381 (CA)	11.08
Saccharin Corp v Anglo-Continental Chemical Works (1900) 17 RPC 307 (HC)	10.04, 22.33
Schering's Applications [1985] IPD 8032 (Pat Ct)	13.47
Secretary of State for Health and Another v Servier Laboratories (Chancery Division), case No HC-2011-000064, HC-2012-000189, and HC-2012-000188 [2016] EWHC 366 (Ch)	24.68
Servier v Apotex [2008] EWHC Civ 445	12.60
Shanks v Unilever Plc & others [2014] EWHC 1647 (Pat)	20.45
SmithKlineBeecham plc v Apotex Europe Ltd [2003] FSR 30	11.76
Sudarshan Chemical Industries Ltd v Clariant Produkte (Deutschland) GmbH [2013] EWCA Civ 919	12.57
Synthon v SmithKline Beecham [2005] UKHL 59	4.18, 12.59
Synthon BV v Merz Pharma GmbH [2009] EWHC 656 (PAT)	9.35
Takeda's SPC Applications [2003] RPC 3	13.65
Teva Pharmaceutical Industries Ltd and anor v Merrell Pharmaceuticals Inc and ors [2007] EWHC 2276 (Ch)	13.14
Teva v Leo Pharma [2014] EWHC 3096 (Pat)	13.31
Thornhill's Application [1962] RPC 199 (PAT)	18.27–18.28
Unilin Beheer BV v Berry Floor NV [2007] EWCA Civ 364	11.08
Valensi v British Radio Corp Ltd [1973] RPC 337 (CA)	1.06
Virgin Atlantic Airways Limited v Zodiac Seats UK Limited [2013] UKSC 46	11.09
Warner Lambert v Actavis Group and others [2015] EWHC 72 (Pat); [2015] EWHC 223 (Pat); [2015] EWHC 249 (Pat); [2015] EWCA Civ 90; [2015] EWHC 485 (Pat)	13.48
Wheatley v Drillsafe [2001] RPC 133 (CA)	22.18
Windsurfing International Inc v Tabur Marine (GB) Ltd [1985] RPC 59 (CA)	4.23
Wistar's Application [1983] RPC 255 (Pat Ct)	14.74
Yeda Research and Development Company Ltd v Rhone-Poulenc Rorer Inc [2007] UKHL 43	20.63
Young v Bristol Airplane [1944] KB 718 (CA)	10.08

AUSTRALIA

Abbott Laboratories v Corbridge Group Pty Ltd [2002] FCAFC 314 (Full Fed Ct Australia)	18.20
Dura-Post (Aust) Pty Ltd v Delnorth Pty Ltd [2009] FCAFC 81	5.63
General Clutch Corp v Sbriggs Pty Ltd [1997] IPR 359 (Fed Ct Australia)	18.20

BELGIUM

Roche v Wellcome Foundation (CA, Brussels, 2001)	22.57
--	-------

DOMINICAN REPUBLIC

Merck v Libertador Marketing, Decision of Supreme Court of 12 July 2006	5.60
---	------

Table of Cases

FRANCE

Normalu, Scherer v Newmat (Cour de Cassation, 12 June 2007)	11.12
---	-------

GERMANY

Bäckerhefe (1975) 6 IIC 207 (BGH)	14.15
Batteriekastenschnur [1989] GRUR 903 (BGH)	22.20
Carvedilol II, X ZR 236/01, (BGH, 19 December 2006)	13.55
Computernetzwerk-Information, GRUR 2003, Federal Patent Court 17 W (pat) 1/02, 323	5.33
Coriolis Force (OJ 1998, 263) (BGH 10th Civil Senate)	4.54
Faxkarte [2002] GRUR 1046 (BGH)	22.46
Fluoran [1988] GRUR 447 (BGH)	12.22
Geschlitzte Abdeckfolie, ZR 29/88 X, [1990] GRUR 505 (Federal Supreme Court)	12.78
Hydropyridine II, X ZB 4/83, C 2/84 215 (BGH)	13.43
Klinische Versuch I, X ZR 99/92, (OJ 1997, 588); [1997] RPC 623 (BGH)	10.47
Klinische Versuch II, X ZR 68/94, (OJ 1997, 589) (BGH)	10.47
Knochenzellenpräparat [1996] GRUR 868 (BPG)	13.55
Olanzapine, X ZR 89/07, Mitt. 3/2009, 119 (BGH 2008)	4.11, 12.22
Patented Feedingstuffs [1989] CMLR 902 (BVerfG)	24.18
Schneidmesser I, Schneidmesser II, Custodiol I, Custodiol II, Kunststoffrohrteil [2002] GRUR 511 (BGH)	22.20
Terfenadine [1988] FSR 145 (Munich Oberlandesgericht)	13.12, 13.15
Tylosin, Re [1977] 1 CMLR 460 (BGH)	21.17
Warner-Lambert v Aliud Pharma, Landgericht Hamburg, Case no 327 O 140/15 (May 2015)	13.48
X ZR 56/09 (BGH)	24.21

INDIA

Novartis AG v Union of India (UOI) and Ors, Civil Appeal Nos 2706–2716 of 2013 (Supreme Court of India)	12.79
--	-------

ITALY

BL Macchine Automatiche v Windmoeller [2004] Rivista di diritto industriale 2 (Corte di 22.58, Cassazione, 19 December 2003)	22.58
---	-------

JAPAN

Aruze Corp v Sammy Corp (Tokyo District Court, 19 March 2002)	10.97
BBS Kraftfahrzeugtechnik AG v Jap Auto Products, Case no H-7(o) 1988 (Japanese Sup Ct, 1 July 1997)	10.23
Fujitsu v Texas Instruments (Japanese Sup Ct, 11 April 2000)	10.98
Hitachi Ltd v Seiji Yonezawa, 14 (NE) 6451 (Tokyo High Ct, 29 January 2004)	20.52
Nichia Corp v Shuji Nakamura, 13 (WA) 17772 (Tokyo Dist Ct, 30 January 2004)	20.52
Olympus Corp v Shumpai Tanaka Heisei, 1256 (Jap Sup Ct, 22 April 2003) (JYU)	20.51
Otsuka/Procaterol Hydrochloride (Tokyo Dist Ct) 7430/1966	10.47
Tsubakimoto Seiki v THK Co (Japanese Sup Ct, 24 February 1998)	22.29

Table of Cases

NETHERLANDS

Bristol-Myers Squibb v Yew Tree (1997) 2255 Scrip 9 (District Court, The Hague)	13.54
Expandable Grafts v Boston Scientific (CA, The Hague, 23 April 1998)	22.55
Follicle Stimulating Hormone II, (OJ 1998, 278) (Hoge Raad)	4.54
Lincoln v Interlas (1989) 404 NJ 1597 (Hoge Raad)	22.53
Monsanto Technology v Cefetra (The Hague District Court, 24 September 2008)	15.26
Mundipharma Pharmaceuticals BV v Sandoz BV, District Court of The Hague of 7 April 2010, Case no 340373/09-2029	12.35
Novartis AG v Sun Pharmaceutical Industries (Europe) B.V., C/09/460540/KG ZA Case file no 200.1 50.713/01 (Court of Appeal, the Hague)	13.48
Van Benthum v Kool (CA, The Hague, 30 March 2000)	22.21

SWITZERLAND

BASF v Geigy 1888	2.37
Kodak II (BG, 1999)	21.17

UNITED STATES OF AMERICA

Abbott Laboratories v Sandoz Inc, 566 F.3d 1282 (Fed Cir 2009)	10.14, 12.46, 18.34
Abbvie Deutschland GmbH & Co v Janssen Biotech Inc, 759 F.3d 1285 (Fed Cir 2014)	14.79
Adams v Burke, 84 US 453 (Sup Ct 1873)	21.17
Alcon Research Ltd v Apotex Inc, 687 F.3d 1362 (Fed Cir 2012)	12.09
Alice Corp Pty Ltd v CLS Bank International, 134 SCt 2347 (US 2014)	4.70
Allergan Inc v Sandoz Inc, 726 F.3d 1286 (Fed Cir 2013)	12.09
Amgen v US International Trade Commission, 14 USPQ2d 1016 (Fed Cir 1990)	12.68
Amgen Inc v Chugai Pharmaceutical Co, 927 F.2d 1200 (Fed Cir 1991)	14.51
Androgel Antitrust Litigation (No II), In re, 687 F. Supp 2d 1371 (ND Ga 2010)	25.15
Argedoulis, In re, 168 USPQ 99 (CCPA 1970)	14.11
Ariad Pharmaceuticals Inc v Eli Lilly & Co, 560 F.3d 1360 (Fed Cir 2007, en banc)	14.55, 14.61, 15.44
Ariad Pharmaceuticals Inc v Eli Lilly & Co (Fed Cir 3 April 2009)	18.47
Ariad Pharmaceuticals Inc v Eli Lilly & Co, 598 F.3d 1336 (Fed Cir 2010, en banc)	14.56, 17.34, 18.47
Aristocrat Technologies Australia v International Game Technologies, 521 F.3d 1328 (Fed Cir 2008, certiorari requested)	11.35
Aronson v Quick Point Pencil Co, 201 USPQ 1 (Sup Ct 1979)	25.26
Association for Molecular Pathology v Myriad Genetics Inc, 133 SCt 2107 (Sup Ct 2013)	4.39, 14.41–14.43, 15.06
Atlantic Thermoplastics Co v Faytex Corp, 970 F.2d 834 (Fed Cir 1992)	10.14
Bayer AG v Housey Pharmaceuticals Inc, 340 F.3d 1367 (Fed Cir 2003)	10.33, 21.48
Bayer AG v Housey Pharmaceuticals Inc, 189 Fed Appx 969 (Fed Cir 2006)	21.48
Bell, In re, 26 USPQ2d 1529 (Fed Cir 1993)	14.45
Bilski v Kappos, 561 US 593 (2010)	4.70
Bio-Technology General Corp v Genentech Inc, 80 F.3d 1553 (Fed Cir 1996)	10.32
Biomedical Patent Management Corp v State of California, 505 F.3d 1328 (Fed Cir 2007)	10.43
Board of Education et al v American Bioscience Inc et al, 67 USPQ2d 1252 (Fed Cir 2003)	20.21
Bogese, In re, 64 USPQ 2d 1448 (Fed Cir 2002)	8.73
Brenner v Manson, 383 US 519 (Sup Ct 1966)	15.10

Table of Cases

Bristol-Myers Squibb Co v Teva Pharmaceuticals USA Inc, 752 F.3d 967 (Fed Cir 2014)	12.09
Brouwer, In re, 37 USPQ2d 1663 (Fed Cir 1995)	12.68
Caraco v Forest Labs, 527 F.3d 1278 (Fed Cir 2008)	11.27
CAT Tech v Tubemaster, 528 F.3d 871 (Fed Cir 2008)	11.28
Centocor Ortho Biotech Inc v Abbott Laboratories, 636 F.3d 1341 (Fed Cir 2011)	14.75, 14.79
Certain Recombinant Erythropoietin, In the Matter of, 10 USPQ2d 1906 (ITC 1989)	12.68
Chiron Corp v Genentech Inc, 70 USPQ2d 1321 (Fed Cir 2004)	14.79
Ciprofloxacin Hydrochloride Antitrust Litigation, In re, 544 F.3d 1323 (Fed Cir 2008) . . .	25.14
Consumer Watchdog v Wisconsin Alumni Research Foundation, 753 F.3d 1258 (Fed Cir 2014)	8.75
Cuno Engineering Corp v Automatic Devices Corp, 314 US 84 (Sup Ct, 1941)	2.23
Dawson Chemical Co v Rohm & Haas Co 206 USPQ 385 (Sup Ct 1980)	22.35–22.37, 22.39
Deepsouth Packing Co v Laitram Corp, 406 US 518 (1972)	10.30
Deuel, In re, 51 F.3d 1552 (Fed Cir 1995)	4.44–4.45, 14.45–14.46
Diamond v Chakrabarty, 447 US 303 (Sup Ct 1980)	14.09, 14.41, 15.20
Donohue, In re, 207 USPQ 196 (CCPA 1980)	19.24
Dr Reddy's Laboratories Ltd v aaiPharma Inc, 64 PTCJ 555 (SDNY 2002)	11.25
Dr Voda v Cordis Corp, 536 F.3d 1311 (Fed Cir 2008)	22.28
Driscoll, In re, 195 USPQ 431 (CCPA 1977)	17.30
Durden, In re, 226 USPQ 359 (Fed Cir 1985)	12.68
E. Bement & Sons v La Dow, 66 Fed 185 (Cir Ct NY 1895)	10.00
eBay Inc v MercExchange LLC, 126 SC 1837 (2006)	10.82
Eli Lilly and Co v Barr Laboratories Inc et al, 55 USPQ 2d 1609 (Fed Cir 2000); 55 USPQ 2d 1869 (Fed Cir 2001)	8.71
Enzo Biochem Inc v Calgene Inc, 29 USPQ2d 1679 (E Cal 1994)	15.18
Enzo Biochem Inc v Gen-Probe Inc et al, 62 USPQ2d 1289 (Fed Cir 2002)	14.53
Enzo Biochem Inc v Gen-Probe Inc et al, 63 USPQ2d 1609 and 1618 (Fed Cir 2002)	14.54, 17.34
Epilady <i>see</i> Improver Corp v Remington Consumer Products Ltd	
Ethicon Inc v US Surgical Corp, 45 USPQ2d 1545 (Fed Cir 1998)	20.59
Ferring BV & Aventis Pharmaceuticals v Barr Laboratories, 437 F.3d 1181 (Fed Cir 2006) . . .	11.37
Festo Corp litigation	22.00
Festo Corp v Shoketsu Kinzoku KK et al, 56 USPQ2d 1865 (Fed Cir 2000) (Festo VI)	22.25
Festo Corp v Shoketsu Kinzoku KK et al, 62 USPQ2d 1705 (Sup Ct 2002) (Festo VIII)	19.30, 22.27
Festo Corp v Shoketsu Kinzoku KK et al, 68 USPQ2d 1321 (Fed Cir 2003) (Festo X)	22.27
Festo Corp v Shoketsu Kinzoku KK et al, (D Mass 2005) (Festo XI)	22.27
Festo Corp v Shoketsu Kinzoku KK et al, (Fed Cir 2007) (Festo XIII)	22.27
Fischer, In re, 421 F.3d 1365 (Fed Cir 2005)	15.10
Florida Prepaid Postsecondary Education Expense Board v College Savings Bank, 51 USPQ2d 1081 (Sup Ct 1999)	10.42
FTC v Actavis Inc, 570 US 756; 133 S Ct 2223 (Sup Ct 2013)	25.14, 25.16–25.20
FTC v Watson Pharmaceuticals Inc, 677 F.3d 1298 (CA 11 2012)	25.15
Genentech v Novo Nordisk, 42 USPQ 2d 1001 (Fed Cir 1997)	8.72, 10.78
Genentech Inc v Wellcome Foundation Ltd, 31 USPQ2d 1161 (Fed Cir 1994)	14.50
Genzyme v Transkaryotic Therapies Inc, 68 USPQ2d 1596 (Fed Cir 2003)	14.66
Glaxo Operations UK Ltd v Quigg, 13 USPQ 2d 1628 (Fed Cir 1990)	9.25
Goodyear Dunlop Tires Operations S.A. v Brown, 131 SCt 2846 (US 2011)	10.76
Graham v John Deere, 148 USPQ 459 (Sup Ct 1966)	4.42
Graver Tank & Manufacturing Co v Linde Air Products Co, 339 US 605 (1950)	22.22

Table of Cases

Great Atlantic and Pacific Tea Co v Supermarket Equipment Corp, 87 USPQ 303 (Sup Ct, 1950)	2.23
Haas, In re, 580 F.2d 461 (CCPA 1978)	18.33
Hoeksema, In re, 399 F.2d 269 (CCPA 1968)	4.18
Hoffmann-La Roche Inc v Promega Corp, 66 USPQ2d 1385 (Fed Cir 2003)	11.37, 17.48
Honeywell International v Hamilton Sundstrand Co, 370 F.3d 1131 (Fed Cir 2004, en banc)	22.26
Innovus Prime LLC v Panasonic Corp & Panasonic Corp of N. Am. Inc, 2013 US Dist LEXIS 93820 (ND Cal 2 July 2013)	23.02
Integra Lifesciences Ltd et al v Merck KGaA et al, 66 USPQ2d 1865 (Fed Cir 2003)	10.40, 10.45
Jazz Photo Corp v International Trade Commission, 264 F.3d (Fed Cir 2001)	21.18
Jepson, <i>ex p</i> [1917] CD 62 (US Patent Office)	18.36
Johnson & Johnson Associates Inc v R.E. Service Co et al, 62 USPQ2d 1225 (Fed Cir 2002)	22.23
Jones et al, In re, 21 USPQ2d 1941 (Fed Cir 1992)	12.14
K-dur Antitrust Litigation, In re, 686 F.3d 197 (CA3 2012)	25.14
Kawai v Metlesics, 178 USPQ 138 (Fed Cir 1973)	5.20, 17.19
King Drug Co of Florence Inc v SmithKline Beecham Corp, 791 F.3d 388 (3d Cir NJ 2015)	25.19
Kinik Co v ITC, 362 F.3d 1359 (Fed Cir 2004)	10.34
Kirtsaeng v John Wiley & Sons Inc, 133 SCt 1351 (Sup Ct 2013)	21.18
KSR v Teleflex, 550 US 398 (Sup Ct 2007)	4.45–4.48, 14.46
Kubin, In re, 561 F.3d 1351 (Fed Cir 2009)	4.47, 14.46–14.48
Kustom Signals Inc v Applied Concepts Inc, 60 USPQ2d 1135 (Fed Cir 2001)	18.21
Lear v Adkins, 162 USPQ 1 (Sup Ct 1969)	25.24, 25.26
Lexmark International Inc v Impression Prods, 785 F.3d 565 (Fed Cir 2015)	21.18
Limelight Networks Inc v Akamai Techs Inc, 134 SCt 2111 (US 2014)	10.28
Lundak, <i>ex p</i> , 227 USPQ 90 (Fed Cir 1985)	14.11, 14.14
Madey v Duke University, 64 USPQ2d 1737 (Fed Cir 2002)	10.39, 10.42, 10.45
Marion Merrell Dow Inc v Baker Norton Pharmaceuticals Inc, 41 USPQ2d 1127 (SD Fl 1996); [1998] FSR 158	13.12
Markman v Westview Instruments Inc, 38 USPQ2d 1461 (Sup Ct 1996)	10.81, 22.22
Markush, <i>ex p</i> [1925] CD 126 (US Patent Office Board of Appeals)	17.30, 18.31–18.33
May and Eddy, In re, 197 USPQ 601 (CCPA 1978)	12.25
Mayo Collaborative Services v Prometheus Laboratories Inc, 132 SCt 1289 (US 2012)	4.39
Medimmune v Genentech, 549 US 118 (Sup Ct 2007)	11.26, 25.25
Merck & Co Inc v Teva Pharmaceuticals USA Inc, 68 USPQ2d 1857 (Fed Cir 2003)	18.24
Merck KGaA v Integra Lifesciences, 545 US 193 (Sup Ct 2005)	10.41
Moore v Regents of the University of California, 793 P.2d 479 (Sup Ct Cal 1990)	15.59
Muniauction Inc v Thomson Corp and I-Deal (Fed Cir 14 July 2008)	18.02
Net Moneyin v Verisign, 545 F.3d 1359 (Fed Cir 2008)	4.20
New Railhead Manufacturing LLC v Vermeer Manufacturing Co et al, 63 USPQ 2d 1843 (Fed Cir 2002)	5.21
Newman v Quigg, 11 USPQ 2d 1340 (Fed Cir 1989)	4.36
Noelle v Lederman et al, 69 USPQ2d 1508 (Fed Cir 2004)	14.75
Northern Pacific Railway Co v United States, 356 US 1 (Sup Ct 1958)	25.21
Ochiai, In re, 37 USPQ2d 1127 (Fed Cir 1995)	12.68
OddzOn Products Inc v Just Toys Inc, 43 USPQ2d 1641 (Fed Cir 1997)	23.36
O'Farrell, In re, 853 F.2d 894 (Fed Cir 1988)	4.44, 14.46
Oren Tavori v NTP (Fed Cir 2008)	20.16
Ortho-McNeil Pharmaceutical Inc v Lupin Pharmaceuticals Inc, 603 F.3d 1377 (Fed Cir 2010)	9.26

Table of Cases

Otsuka Pharmaceutical Co v Sandoz Inc, 678 F.3d 1280 (Fed Cir 2012)	4.48
Parke-Davis v H.K. Mulford, 189 F 95 (SDNY 1911)	13.18
Peters v Active Mfg, 21 F 319 (WD Ohio, 1884)	22.70
Pfizer v Apotex 480 F.3d 1348 (Fed Cir 2007)	12.09, 12.56
Pfizer v Ranbaxy, 79 USPQ2d 1583 (Fed Cir 2006)	11.35
Pfizer Inc v Dr Reddy's Laboratories Ltd et al, 67 USPQ 2d 1525 (DC NJ); 69 USPQ 2d 2016 (Fed Cir 2004)	9.25–9.26
Pharmaceutical Research & Manufacturers of America v FTC, 790 F.3d 198 (DC Cir 2015)	25.07
Phillips v AWH Corp, 376 F.3d 1382 (Fed Cir 2004, en banc)	22.22
PhotoCure Asa v Kappos, 603 F.3d 1372 (Fed Cir 2010)	9.26
Polaroid Inc v Eastman Kodak Co, 16 USPQ2d 1481 (D Mass 1990)	10.85
Polaroid Inc v Eastman Kodak Co, 228 USPQ 305 (D Mass 1985); <i>upheld</i> 229 USPQ 561 (Fed Cir 1986)	10.85
Princo Corp v ITC and US Philips Corp, 616 F.3d 1318 (Fed Cir 2010, en banc)	25.13
Proveris Scientific Corp v Innovasystems Inc, 536 F.3d 1258 (Fed Cir 2008)	10.41
Quanta v LG Electronics, 128 Sup Ct 2109 (2008)	22.43
Recombinant DNA Technology, In re, 30 USPQ2d 1881 (SD Ind 1994)	25.10
Reiffin v Microsoft Corp, 214 F.3d 1342 (Fed Cir 2002)	18.44
Ritz Camera & Image LLC v SanDisk Corporation, 700 F.3d 503 (Fed Cir 2012)	25.13
Roche Products Inc v Bolar Pharmaceutical Co Inc, 221 USPQ 937 (Fed Cir 1984)	9.23, 10.39, 10.46–10.49, 21.16
Rohm & Haas v Crystal Chemical Co, 220 USPQ 289 (Fed Cir 1983)	22.39
Royal Typewriter Co v Remington Rand Inc, 77 USPQ 517 (2nd Cir 1948)	22.22
Sandoz/Ciba Geigy, Federal Register 62 240 65706 (FTC, 15 December 1997)	25.28
Sanofi-Synthelabo v Apotex Inc No 07-1438 (Fed Cir 12 December 2008)	12.25
Schering Corp v Geneva Pharmaceuticals Inc et al, 67 USPQ2d 1664 (Fed Cir 2003)	13.15
SCM Corp v Xerox Corp, 695 F.2nd, 1195 (CA2 1981)	25.07
Scripps Clinic & Research Foundation v Genentech Inc, 927 F.2d 1565; 18 USPQ2d 1001 (Fed Cir 1991)	10.14
Seagate Technology, In re, 497 F.3d 1360 (Fed Cir 2007, en banc)	10.83, 16.51
Sigma-Tau v Schwetz, 288 F.3d 141 (CA 4th Cir 2002)	13.79
Speas, In re, 273 Fed Appx 945 (Fed Cir 2008)	4.36
SRI International Inc v Advanced Technological Laboratories Inc, 44 USPQ2d 1422 (Fed Cir 1997)	16.51
Standard Oil (Indiana) v United States, 283 US 163 (Sup Ct 1931)	25.23
State Oil Co v Khan, 1997 WL 679424 (Sup Ct 1997)	25.22
Studiengesellschaft Kohle v Shell Oil Co, 42 USPQ2d 1674 (Fed Cir 1997)	18.28
Swanson, In re, 540 F.3d 1368 (Fed Cir 2008)	11.34
Symbol Technologies v Lemelson, 61 USPQ 2d 1515 (Fed Cir 2002)	8.73
Symbol Technologies v Lemelson, 67 PTCJ 258 (Dist Ct Nev 2004)	8.73
Syrrx Inc v Oculus Pharmaceuticals Inc, 64 USPQ2d 1222 (D Del 2002)	10.44
Tafas v Doll, 553 F.3d 1345 (Fed Cir 2009)	18.15
Tafas v Dudas, 541 F. Supp 2nd 805 (ED Va 2008)	18.15
Tamoxifen Citrate Antitrust litigation, In re, 466 F.3d 187 (CA2 2006)	25.14
Teva v Novartis, 482 F.3d 1330 (Fed Cir 2007)	11.27
Teva v Pfizer, 395 F.3d 1324 (Fed Cir 2005, certiorari denied)	11.25
TransCore LP v Elec. Transaction Consultants Corp, 563 F.3d 1271 (Fed Cir 2009)	23.02
TS Tech USA, In re, 551 F.3d 1315 (Fed Cir 2008)	10.76
Underwater Devices Inc v Morrison-Knudson Co, 185 F.3d 1259 (Fed Cir 1983)	10.83
Unigene Laboratories Inc v Apotex Inc, 655 F.3d 1352 (Fed Cir 2011)	4.48
United States v General Electric Co, 272 US 476 (Sup Ct 1926)	25.22
University of California v Eli Lilly, 43 USPQ2d 1398 (Fed Cir 1997)	14.52, 14.54, 17.34
University of Illinois Foundation v Block Drug Co, 112 USPQ 204 (7th Cir 1957)	22.22

Table of Cases

University of Rochester v G.D. Searle and Co Inc et al, 68 USPQ2d 1321 (WD NY 2003); 69 USPQ2d 1886 (Fed Cir 2004)	18.44, 18.46–18.47
Walker Process Equipment Inc v Food Machinery & Chemical Corp, 382 US 172 (Sup Ct 1965)	25.12
Warner-Jenkinson Co Inc v Hilton Davis Chem Co, 41 USPQ2d 1865 (Sup Ct 1997)	22.24
Warner-Lambert Co v Apotex Corp, 316 F.3d 1348 (Fed Cir 2003)	10.27
Weber, In re, 580 F.2d 455 (CCPA 1978)	18.33
Welstead, In re, 174 USPQ 449 (CCPA 1972)	17.30, 19.28
Zenith Electronics v PDI Communications, 522 F.3d 1348 (Fed Cir 2008)	22.70

EUROPEAN COMMISSION DECISIONS

AstraZeneca (Case COMP/A.37.507/F3)	24.64
Commission Decision 2006/857/EC Astra Zeneca (Case COMP/A.37.507/F3)	9.34
J&J and Novartis, Press Release IP/13/1233 (10 December 2013)	24.69
Lundbeck (Case COMP/AT.39226) C(2013) 3803 (19 June 2013)	24.67, 25.14
Microsoft (Case T–201/04)	24.50
Servier (Perindopril) (COMP/AT.39612), C(2014) 4955 (9 July 2014)	24.68, 25.14

EUROPEAN COURT OF JUSTICE AND COURT OF FIRST INSTANCE

AEG v Commission [1984] 3 CMLR 325 (ECJ)	24.54
AHP Manufacturing BV v Bureau voor de Industriële Eigendom, Case C–482/07	9.40
Akzo Nobel Chemicals and Akcros Chemicals v Commission, Case C–550/07 (CJEU 2010)	24.53
Arrow Group and Arrow Generics/Commission, Case T–467/13 (Gen Ct, 9th Chamber)	24.67
AstraZeneca v EU Commission, Case T–321/05 (Gen Ct)	24.64
AstraZeneca v EU Commission, Case C–457/10 P (2012) (ECJ)	9.34, 24.64–24.66
AstraZeneca A/S v Lægemiddelstyrelsen, Case C–223/01 (ECJ)	24.64
Bayer v Commission (ECJ 2004)	24.22–24.23
Bayer Crop Science v Deutsches Patent- und Markenamt, Case C–11/13 (19 June 2014)	13.64
Biogen v SmithKline Beecham, Case C–181/95, [1996] ECR I–00717	9.40
Boehringer Ingelheim KG v Swingward Ltd II, Case C–348/04 (ECJ)	24.20
Brüstle, Case C–34/10 (ECJ)	24.12
Centrafarm v Sterling Drug [1974] CMLR 1, Case 15/74 (ECJ)	24.16
Consten & Grundig v Commission [1966] CMLR 418, Case 54/64 (ECJ)	24.15
COPAD v Dior, Case C–59/08 (ECJ)	24.25
Davidoff v Levi Strauss, Case C–414/99 (ECJ)	24.20
Farmitalia Carlo Erba Srl's SPC Application, Case C–392/97 [2000] RPC 580 (ECJ)	13.60
French Republic v Commission of the European Communities, Case C–277/98 (ECJ)	15.28
Gat v Luk, Case C–4/03 (ECJ, 2006)	22.59
Generics (UK)/Commission, Case T–469/13 (Gen Ct, 9th Chamber)	24.67
Georgetown University, University of Rochester, Loyola University of Chicago v Comptroller General of Patents, Case C–422/10 (24 November 2011)	13.65
GlaxoSmithKline Biologicals SA and others v Comptroller General of Patents, Case C–210/13	13.64
GlaxoSmithKline Services v Commission, Case T–168/01 (CFI)	24.20
GlaxoSmithKline Services v Commission, Case C–501/06 (ECJ)	24.20, 24.24
Hässel v Ratiopharm, Case C–127/00, [2004] ECR I–14781	9.33, 24.64
IMS Health v NDC GmbH (ECJ 2004), Case C–418/01 (ECJ)	24.50
Lundbeck/Commission, Case T–472/13 (Gen Ct, 9th Chamber)	24.67–24.68

Table of Cases

Massachusetts Institute of Technology, Case C-431/04 (ECJ, 4 May 2006)	13.62
Medeva v Comptroller-General of Patents, Case C-322/10 (ECJ, 24 November 2011)	13.65
Merck Genéricos v MSD, Case C-431/05 (CJEU, 11 September 2007)	9.15
Merck v Stephar [1981] CMLR 463, Case 187/80 (ECJ)	24.17
Merck/Commission, Case T-470/13 (Gen Ct, 9th Chamber)	24.67
Monsanto Technology LLC v Cefetra BV and Others, Case C-428/08 (ECJ)	15.26, 24.12
National Panasonic v Commission [1980], Case C-136/79) 3 CMLR 325 (ECJ)	24.53
Novartis/Millennium Pharmaceuticals, Cases C-207/03 and C-252/03 [2005]	
ECR I-3209	9.38
Nungesser & Eisele v Commission, <i>sub nom</i> Maize Seeds Case [1983]	
1 CMLR 278 (ECJ)	24.32
Orifarm A/S and Paranova Danmark A/S v Merck Sharp & Dohme Corp, Joined	
Cases C-400/09 and C-207/10 (ECJ)	24.20
Paranova Oy v Lakemedelsverket, Case C-113/01 (ECJ)	24.64
Pharmon v Hoechst [1985] 3 CMLR 775, Case 19/84 (ECJ)	24.18
Radio Telefís Éireann v Commission (Magill), Cases C-241/91 and C-242/91	
(ECJ 1995)	24.50
Regents of University of California v <i>et al</i> , Case C-2/3065 (DC, The Hague,	
22 October 2003)	22.55
Roche v Primus, Case C-539/03 (ECJ 2006)	22.59
Sandoz GmbH v Commission, Cases T-15/04 and T-105/04 (CFI)	14.99
Sandoz Prodotti Farmaceutici v Commission [1989] 4 CMLR 628 (ECJ)	24.21
Seattle Genetics, Case C-471/14	9.37
Sot Lelos Kai Sia EE v GlaxoSmithKline AVE Farmakeftikon Proionton, Joined	
Cases C-468/06c to C-478/06 [2008] ECR I-7139 (ECJ)	24.20, 24.22
Sun Pharmaceutical Industries and Ranbaxy (UK) v Commission, Case T-460/13	
(Gen Ct, 9th Chamber)	24.67
Syfait I, Case C-53/03 (ECJ)	24.20, 24.22
Synthon BV v Merz Pharma GmbH, Case C-195/09	9.35
Xellia Pharmaceuticals and Alpharma/Commission, Case T-471/13	
(Gen Ct, 9th Chamber)	24.67
Zino Davidoff v A & G Imports; Levi Strauss v Tesco; Levi Strauss v Costco (ECJ 2001),	
Cases C-414/99 and C-416/99 (ECJ)	24.26

EUROPEAN PATENT OFFICE

HOWARD FLOREY/Relaxin [1995] EPOR 541 (Opposition Division)	15.03, 15.60
G 5/83 (OJ 1985, 64) EISAI/Second medical indication	12.76, 13.45
G 1/84 (OJ 1985, 299) MOBIL OIL/Opposition by proprietor	11.45
G 2/88 (OJ 1990, 93) MOBIL OIL III/Friction reducing additive	11.65, 12.77
G 6/88 (OJ 1990 114) BAYER/Plant growth regulating agent	12.77
G 1/89 and G 2/89 (OJ 1991, 155 and 166) Non-unity a posteriori	19.09
G 3/89 (OJ 1993, 117) Correction under Rule 88	7.25
G 1/91 (OJ 1992, 253) SIEMENS/Unity	11.66
G 2/91 (OJ 1992, 206) KROHNE/Appeal fees	7.42
G 9/91 (OJ 1993, 408) ROHM & HAAS/Power to examine	11.61
G 10/91 (OJ 1993, 420) Examination of opposition—appeals	11.61
G 11/91 (OJ 1993, 125) CELLTRIX/Glu-Gln	7.25
G 12/91 (OJ 1994, 285) NOVATOME II/Final Decision	7.20
G 1/92 (OJ 1993, 277) Availability to the public	4.10
G 2/92 (OJ 1993, 591) Non-payment of further search fees	19.04
G 3/92 (OJ 1994, 607) LATCHWAYS/Unlawful applicant	7.47, 20.70
G 4/92 (OJ 1994, 149) Basis of decisions	11.56
G 9/92, G 4/93 (both at OJ 1994, 875) BMW (MOTOROLA)/Non-appealing party	7.43

Table of Cases

G 10/92 (OJ 1994, 663) Divisional application	7.30
G 1/93 (OJ 1994, 541) ADVANCED SEMICONDUCTOR/Limiting feature	11.64
G 2/93 (OJ 1995, 275) UNITED STATES OF AMERICA/Hepatitis A virus	17.56
G 3/93 (OJ 1995, 18) Publication in priority year	5.22
G 7/93 (OJ 1994, 775) WHITBY RESEARCH/Late amendments	7.19
G 8/93 (OJ 1994, 887) SERWANE/Withdrawal of opposition	7.42
G 9/93 (OJ 1994, 891) PEUGEOT/Opposition by patent proprietor	11.45
G 10/93 (OJ 1995, 172) SIEMENS/Scope of examination in ex parte appeal	11.60
G 1/94 (OJ 1994, 787) ALLIED COLLOIDS/Intervention	11.59
G 3/95 (OJ 1996, 169)	15.24
G 7/95 (OJ 1996, 626) ETHICON/Fresh grounds of opposition	11.61
G 1/97 (OJ 2000, 322) ETA	7.37
G 3/97 (OJ 1999, 245) INDUPAK; G 4/97 (OJ 1999, 270) GENENTECH	11.45
G 1/98 (OJ 2000, 111) NOVARTIS/Transgenic plants	15.25
G 2/98 (OJ 2001, 62) Priority claiming	5.22
G 3/98 (OJ 2001 62) Grace period	4.54
G 3/99 (OJ 2003, 347)	15.65
G 1/03 (OJ 2004, 413) PPG/Disclaimer	12.33, 12.35
G 2/03 GENETIC SYSTEMS/Disclaimer (OJ 2004.418)	12.33, 12.35
G 2/06 (OJ 2009, 306) WISCONSIN ALUMNI RESEARCH FOUNDATION/ Stem cells	4.35, 15.45
G 2/07 (OJ 2012, 130) PLANT BIOSCIENCE/Broccoli	15.26
G 1/08 (OJ 2012, 206) STATE OF ISRAEL/Tomatoes	15.26
G 2/08 (OJ 2010, 454) ABBOTT RESPIRATORY (formerly KOS LIFE SCIENCES)/Dosage regimen	13.50, 13.53–13.54
G 4/08 (OJ 2010, 572) MERIAN/Languages	6.35
G 2/10 (OJ 2012, 376) SCRIPPS/Disclaimers	12.35
G 3/14 (OJ 2015, to be published) FREEDOM INNOVATIONS/Coatings	11.66
G 1/15, pending, decision expected by the end of 2016	4.16
J 8/82 (unpublished) FUJITSU/Designation of inventors	20.12
J 15/85 (OJ 1986, 395) Abandonment of claim	19.55
J 22/86 (OJ 1987, 280) MEDICAL BIOLOGICAL/Disapproval	7.35
J 3/87 (OJ 1989, 3) MEMTEC/Membranes	7.01
J 11/91 and J 16/91 (consolidated) (OJ 1994, 28) DOW/Deadline for filing divisional application	7.30
R 7/09 (Unpublished) OLYMPUS/Relevant document not received	7.37
R 3/10 (Unpublished) SALMON BRANDS/Argument on inventive step not heard	7.37
R 15/11 (Unpublished) IVIS TECHNOLOGIES/Fundamental violation of Article 113, EPC	7.37
R 21/11 (Unpublished) BAYER/Relevant request not decided	7.37
R 19/12 (Interlocutory decision of 25 April 2014, unpublished) ANONYMOUS/Suspected partiality	7.39
T 1/80 (OJ 1981, 206) BAYER/Carbonless copying paper	4.29
T 12/81 (OJ 1982, 296) BAYER/Diastereomers	12.15
T 24/81 (unpublished) BASF/Metal refining	4.29
T 11/82 (OJ 1983, 479) LANSING BAGNALL/Control circuit	17.27
T 128/82 (OJ 1984, 164) HOFFMANN-LA ROCHE/Pyrrolidone derivatives	13.35
T 150/82 (OJ 1984, 309) IFF/Claim categories	12.43, 18.26
T 154/82 (unpublished) AUSTRALIAN NAT. UNIVERSITY/Metal complexes	12.08
T 181/82 (OJ 1984, 401) CIBA-GEIGY/Spiro compounds	12.21
T 49/83 (OJ 1984, 112) CIBA-GEIGY/Propagating material	15.23
T 220/83 (OJ 1986, 249) HULS/Grounds for appeal	7.45
T 13/84 (OJ 1986, 253) SPERRY/Reformulation of the problem	18.37
T 66/85 (OJ 1989, 167) AMP/Connector	7.24

Table of Cases

T 99/85 (OJ 1987, 413) BOEHRINGER/Diagnostic agent	18.37
T 260/85 (OJ 1989, 105) AMP/Coaxial connector	7.24
T 292/85 (OJ 1989, 275) GENENTECH/Polypeptide expression	11.52, 14.56
T 7/86 (OJ 1988, 381) DRACO/Xanthines	12.15
T 19/86 (OJ 1989, 24) DUPHAR/Pigs II	13.52
T 219/86 (OJ 1988, 254) Naming of opponent	11.45
T 290/86 (OJ 1992, 414) ICI/Cleaning plaque	13.52
T 433/86 (unpublished) ICI/Diisocyanates	12.33
T 118/87 (OJ 1991, 474) CPC/Amylolytic enzyme	17.56
T 124/87 (OJ 1989, 491) DU PONT/Copolymers	12.31
T 139/87 (OJ 1990, 68) BENDIX/Governor valve	7.46
T 296/87 (OJ 1990, 195) HOECHST/Enantiomers	12.24
T 301/87 (OJ 1990, 335) BIOGEN/Alpha-interferon	11.66
T 301/87 (OJ 1990, 335) BIOGEN/Recombinant DNA	5.22
T 305/87 (OJ 1991, 429) GREHAL/Shear	4.20
T 145/88 (OJ 1991, 251) NICOLON/Statement of grounds	7.45
T 461/88 (OJ 1993, 295) HEIDELBERGER DRUCKMASCHINEN/Microchip	4.10
T 418/89 (OJ 1993, 20) ORTHO/Monoclonal antibody	11.50, 14.76
T 482/89 (OJ 1992, 646) TELEMCHANIQUE/Power supply unit	4.07
T 552/89 (unpublished) TETRA PAK/Cold cathode	4.30
T 666/89 (OJ 1993, 495) UNILEVER/Washing composition	12.31
T 19/90 (OJ 1990, 476) HARVARD/Transgenic Mouse	15.21
T 689/90 (OJ 1993, 616) RAYCHEM/Event detector	17.62
T 711/90 (unpublished) POST OFFICE/Optical fiber glass	18.19
T 893/90 (unpublished) QUEEN'S UNIVERSITY KINGSTON/Controlling bleeding	13.52
T 409/91 (OJ 1994, 653) EXXON/Fuel oils	11.52
T 435/91 (OJ 1995, 188) UNILEVER/Detergents	11.52
T 759/91 and T 522/91 (unpublished) AMOCO/Polyamide	18.19
T 465/92 (OJ 1996, 32) ALCAN/Aluminium alloys	4.29
T 472/92 (OJ 1998, 161) SEKISUI/Joint Venture	7.34
T 645/92 (unpublished) SHELL/Lactones	4.29
T 923/92 (OJ 1996, 564) GENENTECH/Human t-PA (EP 93619)	14.44
T 939/92 (OJ 1996, 309) AGREVO/Triazoles	12.19
T 952/92 (OJ 1995, 755) FISON/Prior use	4.10
T 1048/92 (unpublished) PFIZER/Penem derivatives; and T 1046/97 (Unpublished) ZENECA/Enantiomer.	12.24
T 51/93 (unpublished) SERONO/HCG	13.52
T 74/93 (OJ 1995, 712) BTG/Contraceptive method	15.54
T 254/93 (OJ 1998, 285) ORTHO PHARMACEUTICAL/Prevention of skin atrophy	13.52
T 356/93 (OJ 1995, 545) PLANT GENETIC SYSTEMS/Plant cells	15.23, 15.25
T 590/93 (OJ 1995, 337) KOGYO GIJUTSUIN/Photosensitive resins	11.45
T 401/94 (unpublished) ELF ATOCHEM/Novelty—selection invention	12.15
T 138/95 (unpublished) GENENTECH INC/Intrapulmonary	13.52
T 241/95 (OJ 2001, 103) ELI LILLY/Serotonin receptor	13.54
T 337/95 (OJ 1996, 628) NIHON NOHYAKU/Lower alkyl	17.51
T 233/96 (unpublished) MEDCO RESEARCH/Adrenaline	13.52
T 990/96 (OJ 1998, 489) NOVARTIS/Erythro compounds	12.30
T 0400/97 (unpublished) CELLTECH/Immunoglobulins	14.77
T 1212/97 (unpublished) GENENTECH/Immunoglobulin preparations	14.77
T 728/98 (OJ 2001, 319) ALBANY/Pure terfenadine	12.30
T 998/99 (OJ 2005, 229) L'OREAL/Skin equivalent	5.24
T 278/00 (OJ 2003, 546) ELI LILLY/Naphthyl compounds	7.48
T 786/00 (unpublished) GENERAL ELECTRIC COMPANY/Polycarbonates	12.30

Table of Cases

T 90/03 (Unpublished) BASF/Phytase	12.30
T 1020/03 (OJ 2007, 204) GENENTECH/Method of administration of IGF-1 ...	13.53–13.54
T 857/04 (unpublished) DEGUSSA/Verwendung von R—(+) alpha-Liponsäure	12.27
T 998/04 (unpublished) ROMARK LABORATORIES/Tizoxanide	12.08
T 794/05 ASTRAZENECA/Asthma combination (Unpublished)	11.77
T 0794/05 (unpublished) ASTRAZENECA/Asthma combinations	13.28
T 1210/05 (unpublished) TAKEDA/2-(2-pyridylmethylsulfinyl)benzimidazole crystals ...	7.34
T 1443/05 (unpublished) THOR/Synergistic biocide composition	5.22
T 1459/05 (unpublished) EPM-PABST LANDSHUT/Ventilation device	11.66
T 1063/06 (Unpublished) BAYER SCHERING/Reach through claim	18.50
T 1772/06 (unpublished) ABBOTT/Clarithromycin	11.67
T 1719/08 (unpublished) ORGANON/Chroman derivatives	13.08
T 2036/08 (unpublished) SAGRO SpA/Cupric salts as fungicides	12.33
T 2321/08 (unpublished) SAMSUNG ELECTRONICS/Apparatus and method for receiving/transmitting a signal	17.22
T 612/09 (unpublished) CUBIST PHARMACEUTICALS/Daptomycin	7.48, 11.68
T 1176/09 (unpublished) SANGAMO BIOSCIENCES/Modulation of stem cells	12.33
T 1955/09 (unpublished) OCTOPLUS SCIENCES/Antimicrobial peptides	13.52
T 286/10 (unpublished) BOUYGES/Sécurisation d'un accès à une ressource numérique ...	5.33
T 1496/11 SECURENCY/Self-verifying security documents	4.16
T 2573/11 (unpublished) SAMSUNG/Content List	7.20
T 734/12 (unpublished) GENENTECH/Arthritis patients	11.72
T 1780/12 (unpublished) BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM/Cancer treatment	13.50
T 0542/14 (unpublished) ARX LTD/Storage apparatus	11.72